Reuters Health Information (2004-11-19): HCV coinfection increases mortality in HIV patients
HCV coinfection increases mortality in HIV patients
Last Updated: 2004-11-19 11:15:07 -0400 (Reuters Health)
NEW YORK (Reuters Health) - Despite highly active
antiretroviral therapy (HAART), it appears that hepatitis C virus (HCV)
coinfection significantly increases mortality in patients with HIV
infection, researchers report in the November 15th issue of Clinical
Infectious Diseases. These findings are in contrast with study results
obtained in pre-HAART era.
"The impact of HCV coinfection on HIV survival is controversial due
to conflicting data from several large cohort studies," co-author Dr.
Jodie L. Guest of the Atlanta VA Medical Center told Reuters Health.
To investigate further, Dr. Guest and colleagues "used our large VA
cohort to study the impact of coinfection on survival and found that in
the era of HAART and with longer follow-up, coinfection did adversely
impact the survival of our patients after controlling for important
The researchers found that in 970 HIV-infected patients seen between
January 1997 and May 2001, the prevalence of HCV coinfection was 31.6%.
Co-infection was significantly more likely in patients who were older,
black or injection drug users.
The results of multivariate analysis indicated that survival from
the time of AIDS diagnosis was significantly shorter for coinfected
patients (hazard ratio 1.84), "as was time from HIV diagnosis to death
(HR 2.47)," the researchers report.
Altogether, Dr. Guest concluded, "it is likely that the varying
results seen in the literature are due to cohort and methodological
Clin Infect Dis 2004;39:1507-1513.